{"entity":{"id":"generate-biomedicines","kind":"company","name":"Generate:Biomedicines","aka":[],"tldr":"Generative-AI protein design company (Flagship) that went public in 2026 and is testing an antibody that neutralises leaked ADC payload to reduce side effects.","summary":"Generate:Biomedicines went public in early 2026 (~$400M IPO). Oncology programmes: GB-4362, an MMAE neutraliser with FDA Fast Track for enfortumab vedotin toxicity in urothelial cancer (trial-in-progress at ESMO 2026), and GB-5267, a MUC16 CAR-T with Roswell Park. First AI-designed antibody advanced to phase 3 in a non-oncology indication.","asOf":"2026-09-04","links":[{"label":"Q2 2026 business update","url":"https://www.biospace.com/press-releases/generate-biomedicines-inc-reports-second-quarter-2026-financial-results-and-provides-business-update"}],"tags":["frontier"],"related":[],"cancers":["urothelial","ovarian"],"sections":["ai-computation","adcs","immunotherapy"],"technologies":["ai-drug-design","adc-payload-neutralizer","car-t"],"targets":[],"drugs":["enfortumab-vedotin"],"companies":[],"institutions":["roswell-park"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Somerville, MA","country":"US","companyType":"ai-software","website":"https://generatebiomedicines.com","ticker":"GBIO","investors":["flagship-pioneering"],"funding":[]},"route":"/companies/generate-biomedicines/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"section":[{"id":"ai-computation","kind":"section","name":"AI & Computation","route":"/fronts/ai-computation/"},{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"adc-payload-neutralizer","kind":"technology","name":"ADC payload neutralisers","route":"/technologies/adc-payload-neutralizer/"},{"id":"ai-drug-design","kind":"technology","name":"AI-driven drug & target discovery","route":"/technologies/ai-drug-design/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"de-novo-protein-design","kind":"technology","name":"De novo designed protein binders","route":"/technologies/de-novo-protein-design/"}],"drug":[{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/"}],"institution":[{"id":"roswell-park","kind":"institution","name":"Roswell Park Comprehensive Cancer Center","route":"/institutions/roswell-park/"}],"company":[{"id":"flagship-pioneering","kind":"company","name":"Flagship Pioneering","route":"/companies/flagship-pioneering/"}],"bottleneck":[{"id":"b-translational-valley","kind":"bottleneck","name":"The valley of death between lab and product","route":"/bottlenecks/b-translational-valley/"}],"idea":[{"id":"idea-bio1-ai-binders-disordered-regions","kind":"idea","name":"AI-designed proteins that grip the floppy parts of cancer drivers","route":"/ideas/idea-bio1-ai-binders-disordered-regions/"},{"id":"idea-bio1-macrocycle-ppi-campaign","kind":"idea","name":"Macrocyclic peptides to cover protein surfaces that pills cannot","route":"/ideas/idea-bio1-macrocycle-ppi-campaign/"}],"roadmap":[{"id":"drug-discovery-roadmap","kind":"roadmap","name":"Drug discovery roadmap: screening in mice → maps of dependency → designing in silico","route":"/roadmaps/drug-discovery-roadmap/"}]}}